Status:
COMPLETED
Atomoxetine in the Treatment of Binge Eating Disorder
Lead Sponsor:
Lindner Center of HOPE
Collaborating Sponsors:
University of Cincinnati
Conditions:
Binge-eating Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.
Eligibility Criteria
Inclusion
- Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months
- In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization
Exclusion
- Have concurrent symptoms of bulimia nervosa or anorexia nervosa
- Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures
- Patients who are displaying clinically significant suicidality or homicidality
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00327834
Start Date
May 1 2006
End Date
March 1 2007
Last Update
June 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267-0559